Joseph Vittiglio

Directeur des affaires commerciales et juridiques

Finch Therapeutics Group, Inc.bluebird bio, Inc.PepGen Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (9 ops.)

€71k

Latest filing published 02 Mar 2026 for PepGen Inc..

Filing timeline

BuySale

Joseph Vittiglio

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Joseph Vittiglio: trading record in brief

Filings by Joseph Vittiglio span 5 companies, the busiest being AMAG Pharmaceuticals Inc., Aveo Pharmaceuticals, Inc. and bluebird bio, Inc. We count 45 filings; the first trade dates from 24 January 2013 and the latest from 1 March 2026.

The open-market record consists of 9 sales worth €71k, with no purchase. Outside the open market, there are 29 share grants.

The latest filing, published on 2 March 2026, reports a share grant in PepGen Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.